Samsung Biologics Buys GSK's US Plant for $280 Million

The South Korean pharmaceutical contract manufacturer acquires its first US production facility. The plant is expected to have a total capacity of 60,000 liters for pharmaceuticals.

, and Administrator

2025 December 22 . 7:13 AM

1 min read

This image is clicked in a room, where it looks like Store. There are so many bottles in this image... — This image is clicked in a room, where it looks like Store. There are so many bottles in this image and cans. There is a Banner in the middle which is indicating Supra brand. Bottom right corner there is a logo LM.

Samsung Biologics Buys GSK's US Plant for $280 Million

Samsung Biologics is set to purchase its first US production plant from GSK for $280 million (€239 million). The deal marks a major step for the South Korean firm as it expands into American pharmaceutical manufacturing. The facility, located in Rockville, Maryland, will be transferred to Samsung Biologics America, a US subsidiary of the company.

The plant currently belongs to Human Genome Sciences Inc., a GSK-owned operation. Samsung Biologics will take over management once the acquisition is finalised. The deal is expected to complete by the end of the first quarter of 2026, though the final price may still be adjusted.

The facility has a total production capacity of 60,000 liters for pharmaceuticals. Samsung Biologics has announced plans to increase this capacity further. Additional investments will also go towards upgrading the site’s technology and infrastructure.

Once the acquisition is complete, Samsung Biologics will operate its first US-based manufacturing plant. The expanded capacity and modernised equipment will support the company’s growth in the American pharmaceutical market. The deal is scheduled to finalise in early 2026, pending any last-minute adjustments.